HK Stock Market Move | AKESO (09926) rises by over 3%, Cardenil's first-line treatment for stage III gastric cancer has been approved by the FDA to conduct international clinical trials.

AKESO (09926) rose more than 3%, as of the time of writing, it rose by 3.83% to 121.9 Hong Kong dollars, with a turnover of 271 million Hong Kong dollars. On the news front, according to AKESO's official WeChat account, the company recently announced that the global first-in-class PD-1/CTLA-4 bispecific antibody candonilimab in combination with chemotherapy has received approval from the U.S. Food and Drug Administration (FDA) for the international multicenter Phase III clinical study (COMPASSION-37/AK104-311) for the first-line treatment of unresectable or metastatic HER2-negative, untreated gastric or gastroesophageal junction adenocarcinoma. It is reported that the COMPASSION-37 study is the second international multicenter registration clinical study of candonilimab. Previously, an international registration clinical study of candonilimab treatment for immune-resistant liver cancer has been conducted in the United States. The launch of the COMPASSION-37 study is a critical step forward in the global development of candonilimab and an important move in AKESO's global strategy, which will effectively strengthen the company's leading position in the field of tumor immunotherapy 2.0 on the international stage.